Tripterygium wilfordii Glycosides Upregulate the New Anti-Inflammatory Cytokine IL-37 through ERK1/2 and p38 MAPK Signal Pathways

As a Chinese traditional patent medicine, Tripterygium wilfordii glycosides (TWG) have been approved by the China State Food and Drug Administration (Z32021007) for autoimmune and inflammatory diseases. Application of TWG leads to significant decrease of the inflammatory cytokines, such as IL-6, IL-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sen, Li, Rumeng, He, Suhui, He, Lingge, Zhao, Hang, Deng, Xiaohong, Chen, Zhangquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748296/
https://www.ncbi.nlm.nih.gov/pubmed/29403538
http://dx.doi.org/10.1155/2017/9148523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748296/
https://www.ncbi.nlm.nih.gov/pubmed/29403538
http://dx.doi.org/10.1155/2017/9148523

Ejemplares similares